Peptide Therapy - How It Can Help During Menopause

What Are Peptides, Exactly?

Peptides are short chains of amino acids that act as signaling molecules. They allow cells throughout the body to communicate with one another, and they help to regulate a wide variety of biologic processes. Peptides occur naturally in the body, but they are also manufactured for use in prescription medications and skincare products.

The term "peptide therapy" refers to a broad group of treatments that use peptides to target different receptors and biologic pathways. One popular example of a peptide therapy is GLP-1 receptor agonists which is a class of peptide-based medications used to treat diabetes and obesity.

Other peptide therapies are promoted for menopause-related symptoms, anti-aging, muscle recovery, and libido, although the clinical evidence for these is much more limited.

Although peptides are sometimes offered during menopause, they are different from estrogen, progesterone, and testosterone. Rather than replacing hormones that decline during menopause, peptide therapies work through different signaling systems. 

Why Are Peptides Being Talked About in Menopause Care?

Many women notice that their weight becomes more difficult to manage during perimenopause and menopause due to the hormonal fluctuations that influence metabolism and that can cause a reduction in muscle mass.

Skin changes, loss of energy, and hot flashes are also common menopause symptoms that can be unpredictable and difficult to manage.

Peptide therapies are popular and are widely marketed on social media to women in midlife who might be looking for answers to some of these changes.

Although some peptide medications are designed to regulate appetite and metabolism and  others are marketed for cosmetic or performance-related goals, not every symptom that develops during menopause is driven by the same biologic process, which means not every symptom is likely to respond to peptide therapy.

“A lot of patients hear the word ‘peptide’ and assume these treatments all work in a similar way, but that really isn’t the case. The first question should always be: What symptom are we trying to treat, and is there good evidence that this particular therapy addresses it?” - Dr. Judith Barreiro

GLP-1 Medications: The Peptide Therapy with the Strongest Evidence

Among peptide-based medications, GLP-1 receptor agonists currently have the strongest clinical evidence for use in women in midlife.

GLP-1 is a naturally occurring hormone involved in regulating appetite, blood sugar, and digestion. GLP-1 medications such as semaglutide and tirzepatide mimic or enhance these biologic signals in the body.

Compounded Tirzepatide

Starting at $100

Weekly injection. Personalized dosing for gentler starts and individual goals**

Start Now

Research suggests these medications can be effective for weight loss in appropriately selected perimenopausal and postmenopausal women, especially when they are combined with a healthy diet and exercise. They may improve appetite regulation and metabolic health, but they are not designed to replace estrogen or directly treat menopause symptoms.

Long-term research focused specifically on menopausal populations is still needed, but the available data is encouraging.

How Peptide Therapies Differ from Hormone Replacement Therapy

Although peptide therapy and hormone replacement therapy (HRT) are often discussed during midlife, they are intended to address different underlying physiologic processes. Peptide therapy is often marketed for skin aging, muscle loss, and physical recovery, but the justification for use in these areas has not been established. Peptides are not reproductive hormones and do not treat the symptoms associated with the transition to menopause.

HRT supplements estrogen, with or without progesterone, to help treat symptoms that result from declining hormone levels. HRT is the most effective treatment for vasomotor symptoms such as hot flashes and night sweats. Rather than directly replacing depleted hormones like HRT, peptide therapies like GLP-1s bind to receptors and use the body’s natural signaling pathways to treat various conditions.

In some situations, women might use both HRT and a peptide therapy because the treatments address different health concerns. Researchers are continuing to study how hormone therapy and GLP-1 medications may complement one another because they target different physiologic pathways. However, at this time, there are no peptide treatments approved to specifically work together with HRT to treat menopause related symptoms.

Which Menopause Symptoms Are More Likely to Respond to HRT Versus Peptides?

Choosing the most appropriate therapy depends on which symptoms are present and whether they are primarily hormonal, metabolic, dermatologic, or influenced by multiple factors.

Symptoms that are linked to declining estrogen, including hot flashes, night sweats and vaginal dryness, are more likely to improve with hormone replacement therapy (HRT). Weight gain that develops during perimenopause or menopause may improve with GLP-1 medications in women who meet medical criteria, but these medications are not considered treatments for menopausal symptoms..

Estradiol Vaginal Cream

$119.97

3-month supply

Effective relief for vaginal dryness, itching, burning and the prevention of frequent UTIs.

Start Now

Many women benefit from combining lifestyle strategies with individualized medical therapies rather than relying on a single treatment to address every symptom.

What About Peptides for Skin, Muscle, and "Anti-Aging"?

Many peptide products marketed for anti-aging differ from FDA-approved peptide medications used for specific medical conditions.

Topical skincare peptides are designed to support hydration, collagen signaling, or overall skin appearance. Injectable peptide therapies marketed for muscle growth, recovery, or longevity aim to produce systemic effects but often have much less clinical research supporting their use.

While some investigational peptides show promise in early research, data supporting their routine use for healthy aging remains limited. Claims involving rapid muscle growth, recovery, or reversing aging should be interpreted cautiously until they can be supported by larger, high-quality clinical studies.

Risks, Regulations, and Evidence Gaps

The term “peptide therapy” can be confusing because products marketed under this label vary widely in their quality, regulation, and supporting evidence.

Some peptide medications have undergone extensive clinical testing and received FDA approval for specific indications, while many others have not.

Compounded medications are not FDA-approved. In some situations, licensed healthcare providers may prescribe compounded versions of medications, including peptide therapies such as semaglutide and tirzepatide, when they determine they are appropriate for an individual patient. Because compounded medications do not undergo the same FDA approval process as commercially manufactured prescription drugs, they may differ in potency, purity, dosing consistency, and quality control.

Women considering peptide therapy should work with qualified healthcare professionals who prescribe medications from reputable pharmacies and provide appropriate medical follow-up.

Decisions about peptide therapy during midlife are best made through shared discussions with a menopause-trained physician who can evaluate symptoms, health history, treatment goals, and the available evidence.

Questions to Ask Your Clinician About Peptide Therapy

If you are considering peptide therapy, it can be helpful to first identify which menopause symptoms or health concerns you are looking to address. Ask what condition the peptide is intended to treat and if evidence exists specifically in perimenopausal or postmenopausal women. Discuss whether the treatment is FDA-approved, compounded, or investigational and what that means for safety and expected outcomes. Review potential side effects and how treatment success will be measured. Ask whether menopause hormone therapy or another treatment might better address your symptoms.

Because menopause affects women differently, the most appropriate treatment plan should reflect your individual symptoms, medical history, health goals, and personal preferences.

Frequently Asked Questions

How do peptide therapies differ from traditional Hormone Replacement Therapy (HRT)?

Rather than directly replacing depleted sex hormones like estrogen or progesterone, peptide therapies work through different cellular signaling systems. While HRT directly supplements declining hormones to relieve symptoms like hot flashes and vaginal dryness, peptides act as signaling molecules that bind to receptors to influence specific biologic pathways, such as appetite regulation or glucose metabolism.

Which peptide therapy has the strongest clinical evidence for midlife women?

GLP-1 receptor agonists, such as semaglutide and tirzepatide, currently have the strongest clinical support among peptide therapies for use in perimenopausal and postmenopausal women. When paired with healthy lifestyle changes, GLP-1 medications can effectively improve appetite regulation, blood sugar control, and metabolic health, though they do not replace estrogen or directly treat vasomotor menopause symptoms.

What should women know about the safety and regulation of compounded peptides?

Unlike commercially manufactured prescription drugs, compounded peptide treatments are not FDA-approved and do not undergo the same standard regulatory evaluation. Consequently, compounded peptides can vary significantly in purity, potency, quality control, and dosing consistency, making it critical to work with a qualified healthcare professional who sources treatments from reputable pharmacies.

Reference List

1. The Menopause Society. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028.

2. Mikdachi H, Dunsmoor-Su R. GLP-1 receptor agonists for weight loss for perimenopausal and postmenopausal women: current evidence. Curr Opin Obstet Gynecol. 2025;37(2):97-101. doi:10.1097/GCO.0000000000000944.

3. Naveed M, Perez C, Ahmad E, et al. GLP-1 medication and weight loss: barriers and motivators among 1659 participants managed in a virtual setting. Diabetes Obes Metab. 2025;27(7):3780-3788. doi:10.1111/dom.16266.

4. Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597-1604. doi:10.1056/NEJMoa1105816.

5. Bansal R, Aggarwal N. Menopausal hot flashes: a concise review. J Midlife Health. 2019;10(1):6-13. doi:10.4103/jmh.JMH_7_19.

6. Woyka J, et al. International evidence-based guideline on the assessment and management of menopause. Climacteric. 2024. 

7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated February 2025. Accessed July 10, 2026.

8. U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Updated 2025. Accessed July 10, 2026.

9. U.S. Food and Drug Administration. Compounding Laws and Policies. Updated 2025. Accessed July 10, 2026.